Nuvectis Pharma Inc (NASDAQ:NVCT) shares, rose in value on Thursday, April 16, with the stock price up by 1.90% to the previous day’s close as strong demand from buyers drove the stock to $8.86.
Actively observing the price movement in the last trading, the stock closed the session at $8.70, falling within a range of $8.8 and $9.28. The value of beta (5-year monthly) was -0.12. Referring to stock’s 52-week performance, its high was $11.80, and the low was $4.44. On the whole, NVCT has fluctuated by -1.06% over the past month.
With the market capitalization of Nuvectis Pharma Inc currently standing at about $207.37 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-24.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NVCT’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of NVCT currently trading nearly -2.78% and 9.49% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.36, while the 7-day volatility ratio is showing 9.73% which for the 30-day chart, stands at 11.38%. Furthermore, Nuvectis Pharma Inc (NVCT)’s beta value is -0.02, and its average true range (ATR) is 0.90.
A comparison of Nuvectis Pharma Inc (NVCT) with its peers suggests the former has fared considerably weaker in the market. NVCT showed an intraday change of 1.90% in last session, and over the past year, it grew by 27.01%%.
Data on historical trading for Nuvectis Pharma Inc (NASDAQ:NVCT) indicates that the trading volumes over the past 10 days have averaged 0.12 and over the past 3 months, they’ve averaged 118.83K. According to company’s latest data on outstanding shares, there are 19.50 million shares outstanding.
Nearly 48.25% of Nuvectis Pharma Inc’s shares belong to company insiders and institutional investors own 5.72% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.63 million shares as on 2025-03-31, resulting in a short ratio of 13.2. According to the data, the short interest in Nuvectis Pharma Inc (NVCT) stood at 1144.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.34 million. The stock has risen by 63.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NVCT stock heading into the next quarter.
